Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC, 34874-34875 [2018-15719]
Download as PDF
<![CDATA[
34874
Federal Register / Vol. 83, No. 141 / Monday, July 23, 2018 / Notices
filed. The Secretary will not accept a
document for filing without a certificate
of service.
The Commission has determined that
these reviews are extraordinarily
complicated and therefore has
determined to exercise its authority to
extend the review period by up to 90
days pursuant to 19 U.S.C.1675(c)(5)(B).
Authority: These reviews are being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to section 207.62 of the
Commission’s rules.
Issued: July 18, 2018.
By order of the Commission.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2018–15708 Filed 7–20–18; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–989
(Enforcement)]
Certain Automated Teller Machines,
ATM Modules, Components Thereof,
and Products Containing the Same
Commission Determination Not To
Review an Initial Determination
Amending the Complaint and Notice of
Enforcement Proceeding To Reflect a
Corporate Name Change
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission (‘‘the Commission’’) has
determined not to review an initial
determination (‘‘ID’’) (Order No. 46)
amending the complaint and Notice of
Enforcement Proceeding to reflect a
corporate name change.
FOR FURTHER INFORMATION CONTACT: Ron
Traud, Office of the General Counsel,
U.S. International Trade Commission,
500 E Street SW, Washington, DC
20436, telephone 202–205–3427. Copies
of non-confidential documents filed in
connection with this investigation are or
will be available for inspection during
official business hours (8:45 a.m. to 5:15
p.m.) in the Office of the Secretary, U.S.
International Trade Commission, 500 E
Street SW, Washington, DC 20436,
telephone 202–205–2000. General
information concerning the Commission
may also be obtained by accessing its
internet server at https://www.usitc.gov.
The public record for this investigation
may be viewed on the Commission’s
electronic docket (‘‘EDIS’’) at https://
edis.usitc.gov. Hearing-impaired
amozie on DSK3GDR082PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
19:07 Jul 20, 2018
Jkt 244001
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal, telephone 202–205–1810.
On March
14, 2016, the Commission instituted the
original investigation based on a
complaint filed by Nautilus Hyosung
Inc. (now Hyosung TNS Inc.) of Seoul,
Republic of Korea, and Nautilus
Hyosung America Inc. of Irving, Texas
(collectively, ‘‘Nautilus’’). 81 FR 13149
(Mar. 14, 2016). Pertinent to this action,
the complaint alleged violations of
section 337 of the Tariff Act of 1930, as
amended, 19 U.S.C. 1337, in the
importation into the United States, the
sale for importation into the United
States, and the sale within the United
States after importation of certain
automated teller machines, ATM
modules, components thereof, and
products containing the same by reason
of infringement of any of claims 1–3, 6,
8, and 9 of U.S. Patent No. 8,523,235
(‘‘the ’235 patent’’). Id. The complaint
also alleged infringement of claims 1–3
and 5 of U.S. Patent No. 7,891,551;
claims 1 and 6 of U.S. Patent No.
7,950,655; and claims 1–4, 6, and 7 of
U.S. Patent No. 8,152,165. Those claims
were subsequently terminated from the
investigation. See Order No. 11 (June 30,
2016), Comm’n Notice of Non-Review
(July 27, 2016); Order No. 17 (July 21,
2016), Comm’n Notice of Non-Review
(August 16, 2016). The notice of
institution of the investigation named
Diebold Nixdorf, Incorporated and
Diebold Self-Service Systems, both of
North Canton, Ohio (collectively,
‘‘Diebold’’), as respondents. 81 FR
13149; 82 FR 13501 (Mar. 13, 2017). The
Office of Unfair Import Investigations
(‘‘OUII’’) was not named as a party. 81
FR 13149.
On July 14, 2017, the Commission
found a section 337 violation as to the
’235 patent and issued a limited
exclusion order (‘‘LEO’’) as well as cease
and desist orders (‘‘CDOs’’). 82 FR
33513 (July 20, 2017). The LEO
prohibits the unlicensed entry of
automated teller machines, ATM
modules, components thereof, and
products containing the same that
infringe one or more of claims 1–3, 6,
8, and 9 of the ’235 patent that are
manufactured by, or on behalf of, or are
imported by or on behalf of Diebold
Nixdorf, Incorporated, Diebold SelfService Systems, or any of their
affiliated companies, parents,
subsidiaries, agents, or other related
business entities, or their successors or
assigns. Id. The CDOs prohibit, among
other things, the importation, sale, and
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
distribution of infringing products by
Diebold. Id.
On December 22, 2017, the
Commission instituted the subject
enforcement proceeding based on a
complaint filed by Nautilus, alleging
that Diebold violated the July 14, 2017,
remedial orders issued in the original
investigation and to determine what, if
any, enforcement measures are
appropriate. 82 FR 60762 (Dec. 22,
2017). Diebold is named as a
respondent, and OUII is named as a
party. Id.
On June 22, 2018, the presiding
administrative law judge issued Order
No. 46, the subject ID, which granted an
unopposed motion filed by Nautilus to
amend the complaint and the
Commission’s Notice of Enforcement
Proceeding to reflect the corporate name
change of Nautilus Hyosung Inc. to
Hyosung TNS Inc. No petitions for
review of the subject ID were filed. The
Commission has determined not to
review the subject ID.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
By order of the Commission.
Issued: July 17, 2018.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2018–15615 Filed 7–20–18; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Catalent Pharma
Solutions, LLC
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 22, 2018. Such persons
may also file a written request for a
hearing on the application on or before
August 22, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
DATES:
E:\FR\FM\23JYN1.SGM
23JYN1
34875
Federal Register / Vol. 83, No. 141 / Monday, July 23, 2018 / Notices
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
Gamma Hydroxybutyric
Acid.
2010
Schedule
I
The company plans to import finished
dosage unit products containing gammahydroxybutyric acid for clinical trials,
research, and analytical activities.
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
delegated to the Assistant Administrator
of the DEA Diversion Control Division
(‘‘Assistant Administrator’’) pursuant to
section 7 of 28 CFR part 0, appendix to
subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on June
18, 2018, Catalent Pharma Solutions,
LLC, 3031 Red Lion Road, Philadelphia,
Pennsylvania 19114, applied to be
registered as an importer of the
following basic class of controlled
substance:
SUPPLEMENTARY INFORMATION:
Drug
code
Controlled substance
Dated: July 12, 2018
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–15719 Filed 7–20–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: VHG Labs DBA LGC
Standards
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 22, 2018. Such persons
may also file a written request for a
hearing on the application on or before
August 22, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
DATES:
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on April
13, 2018, VHG Labs DBA LGC
Standards, 3 Perimeter Road,
Manchaster NH 03103 applied to be
registered as an importer of the
following basic classes of controlled
substances:
SUPPLEMENTARY INFORMATION:
amozie on DSK3GDR082PROD with NOTICES1
Controlled substance
Drug code
3-Fluoro-N-methylcathinone (3-FMC) ......................................................................................................................
Cathinone ................................................................................................................................................................
Methcathinone .........................................................................................................................................................
4-Fluoro-N-methylcathinone (4-FMC) ......................................................................................................................
Pentedrone (a-methylaminovalerophenone) ...........................................................................................................
Mephedrone (4-Methyl-N-methylcathinone) ............................................................................................................
4-Methyl-N-ethylcathinone (4-MEC) ........................................................................................................................
Naphyrone ...............................................................................................................................................................
N-Ethylamphetamine ...............................................................................................................................................
4-Methylaminorex (cis isomer) ................................................................................................................................
Methaqualone ..........................................................................................................................................................
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) ...........................................................................................
SR-18 (Also known as RCS–8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) ........................................
APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide ......................................................
JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole) ...........................................................................................
SR-19 (Also known as RCS–4) (1-Pentyl-3-[(4-methoxy)-benzoyl] indole .............................................................
JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) ......................................................................
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) ..............................................................................................
UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone ..........................................................
AM2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole) ...............................................................................................
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) ..............................................................................................
Ibogaine ...................................................................................................................................................................
Lysergic acid diethylamide ......................................................................................................................................
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) ........................................................................................
Marihuana ................................................................................................................................................................
Mescaline ................................................................................................................................................................
2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine (2C-T-2 ) ....................................................................................
VerDate Sep<11>2014
19:07 Jul 20, 2018
Jkt 244001
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
E:\FR\FM\23JYN1.SGM
23JYN1
1233
1235
1237
1238
1246
1248
1249
1258
1475
1590
2565
6250
7008
7048
7081
7104
7118
7122
7144
7201
7203
7260
7315
7348
7360
7381
7385
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
]]>Agencies
[Federal Register Volume 83, Number 141 (Monday, July 23, 2018)]
[Notices]
[Pages 34874-34875]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-15719]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Catalent Pharma
Solutions, LLC
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before August 22, 2018.
Such persons may also file a written request for a hearing on the
application on or before August 22, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement
[[Page 34875]]
Administration, Attn: Administrator, 8701 Morrissette Drive,
Springfield, Virginia 22152. All request for hearing should also be
sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ,
8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug
Enforcement Administration, Attn: DEA Federal Register Representative/
DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been delegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on June
18, 2018, Catalent Pharma Solutions, LLC, 3031 Red Lion Road,
Philadelphia, Pennsylvania 19114, applied to be registered as an
importer of the following basic class of controlled substance:
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid.............. 2010 I
------------------------------------------------------------------------
The company plans to import finished dosage unit products
containing gamma-hydroxybutyric acid for clinical trials, research, and
analytical activities.
Dated: July 12, 2018
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-15719 Filed 7-20-18; 8:45 am]
BILLING CODE 4410-09-P
